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its behavioral health carve-out implemented interven-
tions directed at primary care physicians and psychia-
trists to improve the recognition and treatment of depres-
sion. A collaborative follow-up study is now under way
to compare more recent data to the original baseline find-
ings to demonstrate improvement in the quality of care
provided to antidepressant patients.
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Little information exists regarding how health mainte-
nance organizations (HMOs) analyze medical technolo-
gies using technology assessment (TA).
OBJECTIVE: To describe characteristics, processes, and
roles of TA in large HMOs.
METHODS: The target survey population was large
HMOs (enrollments 100,000). One hundred and sixty-
five HMOs met this criterion. Corporate consolidation of
HMOs reduced the cohort to 96 HMOs, representing
77% of total US covered lives. A questionnaire was de-
veloped and field tested. The survey was mailed to pre-
identified HMO contacts in early 1998.
RESULTS: Survey response rate was 43%. Of respondents,
85% (35/41) routinely conduct TA. More than 50% of the
time, TA in HMOs includes representatives from medical,
pharmacy, quality improvement, legal, and benefits func-
tions. TA is initiated by HMO medical affairs departments
(70% of the time). HMOs conduct TA on equipment,
procedures, devices, and several types of drugs. All respon-
dents conduct TA either at time of product introduction,
adoption into practice, or upon FDA approval. HMOs con-
duct TA again for one of three reasons: competitive alterna-
tives, new indication, or replacement. Legislative, societal,
and accreditation demands can influence HMOs to conduct
TA. HMOs consider randomized controlled trials, pub-
lished in peer reviewed journals as the most desirable data
source. Other data are used, but were rated less favorably.
Lack of timely data can limit TA. Over 90% of respondents
seek outside assistance for TA. HMOs typically conduct TA
to determine benefits coverage policy.
CONCLUSION: Most HMOs surveyed conduct TA.
Medical staff influence TA in HMOs. HMOs perceive ran-
domized controlled trials as more desirable than other
data. Outcomes data are often not available at time of TA.
HMOs use TA consultants as one source of information.
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OBJECTIVE: Cost-effective data collection is a critical
component of pharmacoeconomic and outcomes studies,
and is often a key limiter of study design and scope. The
objectives of this presentation are to: 1) present a new
method of clinical data collection in the community-based
physician setting, and 2) present statistics on data collected
in 1998. 
METHODS: This presentation focuses on collecting clin-
ical information in the community-based physician set-
ting. This information has broad utility, including sup-
port of the conduct of pharmacoeconomic and outcomes
studies. The data collection process is built around com-
munity-based physicians’ preferred means of document-
ing patient encounters—dictation and transcription. The
data collection process begins with templated physician
dictation to support discrete data element capture. New
transcription technologies that provide for discrete data
element capture, in addition to free text typing, are used
to document the encounter and capture the data ele-
ments. Back-end data scrubbing, natural language encod-
ing, and data mapping are then used to transform physi-
cian natural language into useable data. Techniques for
validating data through source document sampling will
also be presented. 
RESULTS: Data collected from cardiologists through
September 1998 will be presented. Preliminary statistics
include the following: 5865 coronary artery disease pa-
tients were seen; 54.1% of these patients were on a sta-
tin. Of these patients 42.1% were on atorvastatin, 36.7%
were on simvastatin, 11.2% were on pravastatin, and
10.0% were on other statins. Switching patterns between
statins will be presented. Common switching reasons in-
clude formulary changes, ineffectiveness and side effects. 
CONCLUSIONS: Existing clinical documentation pro-
cesses can be leveraged to collect more detailed and mean-
ingful information for pharmacoeconomics and outcomes
studies than traditional, transaction-based information
sources.
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OBJECTIVES: Using prescription claims data, the pri-
mary objective of this study was to evaluate whether uti-
lization differed among various plan characteristics after
controlling for covariates. The secondary objective was
to examine the relationships among plan characteristics
and cost of pharmaceuticals within various therapeutic
categories.
METHODS: Data were obtained from 1996 prescription
claims information for the commercial population ad-
ministered by a Rhode Island–based PBM. There were
29,211 subscribers representing 64,815 enrollees eligible
